Status: Not yet recruiting
A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).
Participants needed: 120
Trial details
Phase: Phase 3Age: 1+Biological sex: AllType: InterventionalSponsor: Jazz PharmaceuticalsUpdated: Jul 24, 2026
Eligibility criteria
Is at least 1 year of age at the time of signing the informed consent/assent. [+12]